Intravenous therapy for moderate-severity CAP in children 2 months or older

For children 2 months or older with moderate-severity CAP who can tolerate and absorb oral therapy, use oral therapy because studies have shown equivalent outcomes to intravenous therapyAddo-Yobo, 2004Atkinson, 2007Hazir, 2008.

For children 2 months or older with moderate-severity CAP who cannot tolerate or absorb oral therapy, use:

benzylpenicillin 50 mg/kg up to 1.2 g intravenously, 6-hourly. See advice on patient review, intravenous to oral switch and duration of therapy. benzylpenicillin

For children 2 months or older with moderate-severity CAP who have had a nonsevere (immediate or delayed) hypersensitivity reaction to a penicillin, use:

1cefotaxime 50 mg/kg up to 2 g intravenously, 8-hourly. See advice on patient review, intravenous to oral switch and duration of therapy cefotaxime

OR

1ceftriaxone 50 mg/kg up to 2 g intravenously, daily. See advice on patient review, intravenous to oral switch and duration of therapy. ceftriaxone

For children 2 months or older with moderate-severity CAP who have had a severe immediate1 hypersensitivity reaction to a penicillin, cefotaxime or ceftriaxone (at the dosage above) can be considered if a beta-lactam antibiotic is strongly preferred (for considerations, see Severe immediate hypersensitivity: Implications of cross-reactivity between penicillins and cephalosporins).

For children 2 months or older with moderate-severity CAP who have had a severe immediate1 hypersensitivity reaction to a penicillin in whom cefotaxime or ceftriaxone is not used, or for children who have had a severe delayed2 hypersensitivity reaction to a penicillin, use:

azithromycin 10 mg/kg up to 500 mg intravenously, daily. See advice on patient review, intravenous to oral switch and duration of therapy. azithromycin

1 Severe immediate hypersensitivity reactions include anaphylaxis, compromised airway, airway angioedema, hypotension and collapse.Return
2 Severe delayed hypersensitivity reactions include cutaneous adverse drug reactions (eg drug rash with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson syndrome/toxic epidermal necrolysis [SJS/TEN], severe blistering or desquamative rash), and significant internal organ involvement (eg acute interstitial nephritis).Return